Belmora has petitioned the Fourth Circuit to reconsider its decision that Bayer did not need to use the Flanax mark in the US to sue under the Lanham Act. Belmora says the court “appeared to be motivated by a sense of ethical outrage”
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
The England and Wales appeals court handed down its judgment just seven working days after hearing the trademark dispute involving pharma company Merck